NeurologyLive® Friday 5 — March 22, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: #PreAANChat: NeurologyLive to Host Pre-AAN 2024 Social Chat

Join us on April 8, 2024, for a social chat ahead of the 2024 American Academy of Neurology Annual Meeting! We will be discussing top sessions, tips and tricks for first-time attendees, and what everyone is looking forward to most at this year’s meeting!

2: IJMSC Online First: March 2024

Here's the latest multidisciplinary multiple sclerosis research published online first in the International Journal of MS Care.

3: Exploring the Potential Therapeutic Avenue of BTK Inhibitors for Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]

4: NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

In this week's NeuroVoices Q&A, the chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.

5: Emerging Class of Medications for Multiple Sclerosis: Examining the Development of BTK Inhibitors

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.